Today we announced we have been awarded up to $41.3 million from the @ARPA_H as part of its Engineering of Immune Cells inside the Body (EMBODY) program to support our in vivo CAR-T therapy efforts. Read more here: https://t.co/qFFIh2E7VA
#FlagshipFounded@TesseraTx announces an agreement with the @gatesfoundation to jointly fund development of globally accessible in vivo genetic therapies for sickle cell disease.
Today, we announced we have entered into an agreement with the @gatesfoundation to jointly fund our in vivo program for sickle cell disease (SCD). Read more here: https://t.co/dQZKfKgP1Z
@yaireinhorn@blueallele@intelliatx Is this company actually “focused on advancing transformational gene editing technologies”, or are they just patent trolls?
@JohnCendpts@rtnarch Nelsen shares that he was once asked about the secret to making deals. His response: "lack of knowledge...You have to have a sense to even be able to question the smartest people whether they’re right or wrong, and you have to have a tolerance for failure”
Pro tip: Translating academic research into drugs is hard. Doing it with a team that’s not equipped, hasn’t done it before, and led by people who “know enough to be dangerous” is a bad recipe. The funds and startups that address this fully will be better positioned to succeed.